Details of the Drug Combination

General Information of Drug Combination (ID: DCUXU5C)

Drug Combination Name
Deferoxamine Deferiprone
Indication
Disease Entry Status REF
Hemochromatosis Phase 1 [1]
Component Drugs Deferoxamine   DMG0C81 Deferiprone   DMS2M7O
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Deferoxamine
Disease Entry ICD 11 Status REF
Acute iron or aluminum toxicity FB83.20 Approved [2]
Subarachnoid hemorrhage 8B01 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 1/2 [4]
Indication(s) of Deferiprone
Disease Entry ICD 11 Status REF
Beta thalassemia 3A50.2 Approved [5]
Iron overload disease 5C64.10 Approved [5]
Thalassemia 3A50 Approved [6]
Deferiprone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Iron (Fe) TTUDR0C NOUNIPROTAC Modulator [7]
------------------------------------------------------------------------------------
Deferiprone Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
UDP-glucuronosyltransferase 1A6 (UGT1A6) DESD26P UD16_HUMAN Metabolism [8]
------------------------------------------------------------------------------------
Deferiprone Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Frataxin, mitochondrial (FXN) OTE9U09A FRDA_HUMAN Increases Expression [9]
Serotransferrin (TF) OT41PEMS TRFE_HUMAN Increases Expression [10]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Cardiovascular Diseases DC7PNEB N. A. Phase 1 [11]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00349453) Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 207384.
3 Deferoxamine FDA Label
4 ClinicalTrials.gov (NCT04333550) Application of Desferal to Treat COVID-19. U.S. National Institutes of Health.
5 Deferiprone FDA Label
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7456).
7 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
8 Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants. Drug Metab Dispos. 2009 Feb;37(2):322-9.
9 Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia. PLoS One. 2013;8(2):e55940.
10 Antiproliferative effect of deferiprone on the Hep G2 cell line. Biochem Pharmacol. 1998 Aug 15;56(4):431-7. doi: 10.1016/s0006-2952(98)00071-9.
11 ClinicalTrials.gov (NCT00115349) Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases